Swiss National Bank maintained its stake in shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) during the second quarter, Holdings Channel reports. The institutional investor owned 182,600 shares of the biopharmaceutical company’s stock at the end of the second quarter. Swiss National Bank owned about 0.14% of Amicus Therapeutics worth $997,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Teachers Advisors Inc. boosted its stake in shares of Amicus Therapeutics by 1.0% in the first quarter. Teachers Advisors Inc. now owns 173,294 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 1,750 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Amicus Therapeutics by 14.4% in the first quarter. Legal & General Group Plc now owns 29,770 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 3,743 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at approximately $157,000. California State Teachers Retirement System boosted its stake in shares of Amicus Therapeutics by 8.8% in the second quarter. California State Teachers Retirement System now owns 267,038 shares of the biopharmaceutical company’s stock valued at $1,458,000 after buying an additional 21,525 shares during the last quarter. Finally, UBS Group AG boosted its stake in shares of Amicus Therapeutics by 37.7% in the first quarter. UBS Group AG now owns 88,282 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 24,155 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.
Amicus Therapeutics Inc. (NASDAQ:FOLD) traded up 3.56% during trading on Wednesday, reaching $7.56. The company’s stock had a trading volume of 1,069,045 shares. The stock’s market cap is $1.07 billion. Amicus Therapeutics Inc. has a 52-week low of $4.98 and a 52-week high of $11.78. The firm has a 50 day moving average price of $7.18 and a 200-day moving average price of $6.94.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.07. On average, analysts expect that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.
Several research firms recently issued reports on FOLD. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Chardan Capital set a $15.00 price target on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $19.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a report on Tuesday, June 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Amicus Therapeutics currently has an average rating of “Buy” and a consensus target price of $12.19.
In related news, insider Hung Do sold 25,000 shares of the stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total value of $175,000.00. Following the sale, the insider now directly owns 583,453 shares of the company’s stock, valued at approximately $4,084,171. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jay Barth sold 20,916 shares of the stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $7.00, for a total transaction of $146,412.00. Following the completion of the sale, the insider now directly owns 25,458 shares in the company, valued at $178,206. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.